×
Choose Speciality

EXPLORE!

LOGIN

Apremilast

  791 Views

Dr KN Sarveswari, Chennai    21 January 2019

  • Orally administered apremilast is an effective generally well-tolerated and convenient option for the treatment of many chronic inflammatory dermatoses. It does not cause immune suppression but acts by targeting the central inflammatory signalling pathways.
  • Hence, it has an added advantage over conventional treatment modalities available. It is not associated with an increased risk of infection or malignancy and no lab monitoring is required.
  • However, a low drug survival beyond 6-8 months as reported in real-world studies limits its use as a long-term maintenance therapy.
  • Availability of 10 mg and 20 mg dosage may widen the scope of its use in various other dermatological diseases. Safety and efficacy in pediatric age group should also be proven.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.